We are monitoring the impact of COVID-19 on APAC Multiple Myeloma Therapeutics Market Get in touch with us for detailed analysis Know More
Share on

Asia Pacific Multiple Myeloma Therapeutics Market Research Report - Segmented By Treatment Type, Drug Type & Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore & Rest of APAC) - Industry Analysis, Size, Share, Growth, Trends & Forecasts (2022 to 2027)

Published: January, 2022
ID: 802
Pages: 140

APAC Multiple Myeloma Therapeutics Market Size & Growth (2022 to 2027)

The multiple myeloma therapeutics market in the Asia Pacific was worth USD 1.59 billion in 2022 and is estimated to be growing at a CAGR of 5.5%, reaching USD 2.08 billion by 2027.

As the frequency of multiple myeloma in the population rises, the Asia Pacific multiple myeloma treatment market is predicted to develop. Multiple myelomas are more frequent in males than in women, and they become more common as people get older. As a result, increasing the older population would surely boost the Asia Pacific Multiple Myeloma Therapeutics Market's growth during the forecast period. According to the World Health Organization (WHO), the aged population will number about 2 billion individuals by 2050.

Furthermore, factors such as the presence of key market players and the rising adoption of innovative therapies have boosted the Asia Pacific multiple myeloma therapeutics market. With many patients and the usage of novel treatments, Asia Pacific is expected to grow the fastest during the projected period. In addition, governments and non-governmental organizations (NGOs) ongoing initiatives to improve patient knowledge of novel treatment alternatives are actively supporting this sector.

The rising frequency of the disease and the aging population are two significant reasons projected to significantly boost the Asia Pacific multiple myeloma treatments market during the forecast period. In addition, supportive interventions, such as reparative treatment, including transfusion, will be included in the complications connected with the care of older individuals.

The Asia Pacific multiple myeloma treatment market is being held back by high treatment prices and legislation and regulations. In addition, the Asia Pacific multiple myeloma treatment market's tiny target patient population is a tough element that will play a vital role over the forecast period.

The COVID 19 pandemic has wreaked havoc on many people's lives in various ways. Patients with myeloma are at an elevated risk of bacterial and viral infections by 7% to 10%. If there are resource concerns because of COVID 19, postponing the stem cell transplant may be an option for transplant-eligible myeloma patients. Most clinical experiments, including cellular therapy trials, were put on hold during the pandemic. As a result, all treatment procedures were postponed in the first half of 2020, resulting in a decrease in market share.

This research report on the APAC multiple myeloma therapeutics market has been segmented and sub-segmented into the following categories

By Treatment Type:

  • Chemotherapy      
    • Anthracycline antibiotic
    • Alkylating agent
  • Targeted Therapy
    • Proteasome inhibitor

By Drug Type:

  • Corticosteroids     
    • Dexamethasone (Decadron)
    • Prednisone (Deltasone/Orasone)
  • Immunomodulatory agents             
    • Thalidomide (Thalomid)
    • Lenalidomide (Revlimid)
    • Arsenic trioxide (Trisenox)
    • Plerixafor (Mozobil)

By Country:

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

The development of innovative treatments with significantly improved clinical outcomes across all stages of the disease and the lack of standard competition in countries like China, Japan, and Australia will fuel the expansion of the multiple myeloma therapeutics market. Evolving multiple myeloma medicines are likely to provide options in the lapsed or refractory disease scenario and the second and third lines of treatment, boosting the APAC market. Furthermore, the limited efficacy of current medications, the rising prevalence of the disease, and the growing elderly population are likely to provide a significant platform for new drug development. Several pipeline pills present process segment III medical trials with superb medical consequences are anticipated to engender a surge withinside the enterprise boom upon the release of those novel pills at some stage in the forecast period.

China is anticipated to dominate the Asia Pacific Multiple Myeloma Therapeutics marketplace at some stage in the forecast period. The presence of massive groups and excessive adoption prices for more modern remedy alternatives are the elements contributing to the region's dominance.

Japan had the second-largest share in the Asia Pacific Multiple Myeloma Therapeutics market in 2020 attributed to factors such as the massive affected person base and developing adoption of novel remedy strategies withinside the region; Japan is anticipated to witness the quickest boom at some stage in the forecast period.

KEY MARKET PLAYERS:

Companies playing a notable role in the APAC multiple myeloma therapeutics market profiled in this report are AB Science SA, AbbVie Inc., Ablynx NV, Acceleron Pharma Inc., IGF Oncology LLC. , ImmunGene Inc., Millennium Pharmaceuticals Inc., MimiVax LLC, Mirna Therapeutics, RedHill Biopharma Ltd., Rhizen Pharmaceuticals S.A., Terpenoid Therapeutics Inc., Teva Pharmaceutical Industries Ltd., TG Therapeutics Inc., and Johnson and Johnson.

1. Introduction                                 

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences

                3.3 New Developments

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

                4.1 Market Drivers

                4.2 Market Restraints

                4.3 Key Challenges

                4.4 Current Opportunities in the Market              

5. Market Segmentation

                5.1 By Treatment Type

                                5.1.1 Chemotherapy

                                                5.1.1.1 Anthracycline antibiotic

                                                5.1.1.2 Alkylating agent

                                5.1.2 Targeted Therapy

                                                5.1.2.1 Proteasome inhibitor

                5.2 By Drug Type                             

                                5.2.1 Corticosteroids      

                                                5.2.1.1 Dexamethasone (Decadron)

                                                5.2.1.2 Prednisone (Deltasone/Orasone)

                                5.2.2 Immunomodulatory agents             

                                                5.2.2.1 Thalidomide (Thalomid)

                                                5.2.2.2 Lenalidomide (Revlimid)

                                                5.2.2.3 Arsenic trioxide (Trisenox)

                                                5.2.2.4 Plerixafor (Mozobil)

6. Geographical Analysis                                              

                6.1 Introduction                               

                6.2 China                             

                6.3 India                              

                6.4 Japan                            

                6.5 South Korea                               

                6.6 Australia                      

7. Pipeline Product Analysis                                        

                7.1 Overview                                    

                7.2 Pipeline Development Landscape                                    

                7.3 Molecular Targets in the Pipeline                                      

                7.4 Clinical Trials (by Stage of Development, Indication, Molecule Type and Molecular Target)

                                7.4.1 Failure Rate            

                                7.4.2 Clinical Trial Duration           

                                7.4.3 Clinical Trial Size    

8. Strategic Analysis                                       

                8.1 PESTLE analysis                         

                                8.1.1 Political     

                                8.1.2 Economic 

                                8.1.3 Social         

                                8.1.4 Technological         

                                8.1.5 Legal          

                                8.1.6 Environmental       

                8.2 Porter’s Five analysis                              

                                8.2.1 Bargaining Power of Suppliers        

                                8.2.2 Bargaining Power of Consumers    

                                8.2.3 Threat of New Entrants     

                                8.2.4 Threat of Substitute Products and Services              

                                8.2.5 Competitive Rivalry within the Industry     

9. Market Leaders' Analysis                                        

                9.1 AB Science SA                            

                                9.1.1 Overview 

                                9.1.2 Product Analysis   

                                9.1.3 Strategic Evaluation and Operations            

                                9.1.4 Financial analysis  

                                9.1.5 Legal issues             

                                9.1.6 Recent Developments       

                                9.1.7 SWOT analysis       

                                9.1.8 Analyst View          

                9.2 AbbVie Inc.                 

                9.3 Ablynx NV                   

                9.4 Acceleron Pharma Inc.                           

                9.5 IGF Oncology LLC.                    

                9.6 ImmunGene Inc.                      

                9.7 Millennium Pharmaceuticals Inc.                       

                9.8 MimiVax LLC                              

                9.9 Mirna Therapeutics                 

                9.10 RedHill Biopharma Ltd.                        

                9.11 Rhizen Pharmaceuticals S.A.                             

                9.12 Terpenoid Therapeutics Inc.                             

10. Competitive Landscape                                         

                10.1 Market share analysis                          

                10.2 Merger and Acquisition Analysis                     

                10.3 Agreements, collaborations and Joint Ventures     

                10.4 New Product Launches                       

11. Expert Opinions                                        

                11.1 Market Outlook                     

                11.2 Investment Opportunities                 

Appendix                                           

                a) List of Tables                

                b) List of Figures                           

  1. Asia-Pacific Multiple Myeloma Therapeutics Market By Region, From 2022 - 2027 (USD Billion)
  2. Asia-Pacific Multiple Myeloma Therapeutics Market By Treatment Type, From 2022 - 2027 (USD Billion)
  3. Asia-Pacific Chemotherapy Market By Region, From 2022 - 2027 (USD Billion)
  4. Asia-Pacific Targeted Therapy Market By Region, From 2022 - 2027 (USD Billion)
  5. Asia-Pacific Multiple Myeloma Therapeutics Market By Drug Type, From 2022 - 2027 (USD Billion)
  6. Asia-Pacific Corticosteroids Market By Region, From 2022 - 2027 (USD Billion)
  7. Asia-Pacific Immunomodulatory agents Market By Region, From 2022 - 2027 (USD Billion)
  8. China Multiple Myeloma Therapeutics Market By Treatment Type, From 2022 - 2027 (USD Billion)
  9. China Multiple Myeloma Therapeutics Market By Drug Type, From 2022 - 2027 (USD Billion)
  10. India Multiple Myeloma Therapeutics Market By Treatment Type, From 2022 - 2027 (USD Billion)
  11. India Multiple Myeloma Therapeutics Market By Drug Type, From 2022 - 2027 (USD Billion)
  12. Japan Multiple Myeloma Therapeutics Market By Treatment Type, From 2022 - 2027 (USD Billion)
  13. Japan Multiple Myeloma Therapeutics Market By Drug Type, From 2022 - 2027 (USD Billion)
  14. South Korea Multiple Myeloma Therapeutics Market By Treatment Type, From 2022 - 2027 (USD Billion)
  15. South Korea Multiple Myeloma Therapeutics Market By Drug Type, From 2022 - 2027 (USD Billion)
  16. Australia Multiple Myeloma Therapeutics Market By Treatment Type, From 2022 - 2027 (USD Billion)
  17. Australia Multiple Myeloma Therapeutics Market By Drug Type, From 2022 - 2027 (USD Billion)
  18. Asia-Pacific Multiple Myeloma Chemotherapy Market By Type, From 2022 - 2027 (USD Billion)
  19. Asia-Pacific Anthracycline Antibiotic Market By Region, From 2022 - 2027 (USD Billion)
  20. Asia-Pacific Alkylating Agent Market By Region, From 2022 - 2027 (USD Billion)
  21. China Multiple Myeloma Chemotherapy Market By Type, From 2022 - 2027 (USD Billion)
  22. India Multiple Myeloma Chemotherapy Market By Type, From 2022 - 2027 (USD Billion)
  23. Japan Multiple Myeloma Chemotherapy Market By Type, From 2022 - 2027 (USD Billion)
  24. South Korea Multiple Myeloma Chemotherapy Market By Type, From 2022 - 2027 (USD Billion)
  25. Australia Multiple Myeloma Chemotherapy Market By Type, From 2022 - 2027 (USD Billion)
  26. Asia-Pacific Anthracycline Antibiotic Multiple Myeloma Chemotherapy Market By Type, From 2022 - 2027 (USD Billion)
  27. Asia-Pacific Melphalan (Alkeran) Market By Region, From 2022 - 2027 (USD Billion)
  28. Asia-Pacific Liposomal doxorubicin (Doxil) Market By Region, From 2022 - 2027 (USD Billion)
  29. China Anthracycline Antibiotic Multiple Myeloma Chemotherapy Market By Type, From 2022 - 2027 (USD Billion)
  30. India Anthracycline Antibiotic Multiple Myeloma Chemotherapy Market By Type, From 2022 - 2027 (USD Billion)
  31. Japan Anthracycline Antibiotic Multiple Myeloma Chemotherapy Market By Type, From 2022 - 2027 (USD Billion)
  32. South Korea Anthracycline Antibiotic Multiple Myeloma Chemotherapy Market By Type, From 2022 - 2027 (USD Billion)
  33. Australia Anthracycline Antibiotic Multiple Myeloma Chemotherapy Market By Type, From 2022 - 2027 (USD Billion)
  34. Asia-Pacific Alkylating Agent Multiple Myeloma Chemotherapy Market By Type, From 2022 - 2027 (USD Billion)
  35. Asia-Pacific Doxorubicin (Adriamycin) Market By Region, From 2022 - 2027 (USD Billion)
  36. Asia-Pacific Cyclophosphamide (Neosar) Market By Region, From 2022 - 2027 (USD Billion)
  37. Asia-Pacific Vincristine (Oncovin) Market By Region, From 2022 - 2027 (USD Billion)
  38. Asia-Pacific Carmustine (BiCNU) Market By Region, From 2022 - 2027 (USD Billion)
  39. China Alkylating Agent Multiple Myeloma Chemotherapy Market By Type, From 2022 - 2027 (USD Billion)
  40. India Alkylating Agent Multiple Myeloma Chemotherapy Market By Type, From 2022 - 2027 (USD Billion)
  41. Japan Alkylating Agent Multiple Myeloma Chemotherapy Market By Type, From 2022 - 2027 (USD Billion)
  42. South Korea Alkylating Agent Multiple Myeloma Chemotherapy Market By Type, From 2022 - 2027 (USD Billion)
  43. Australia Alkylating Agent Multiple Myeloma Chemotherapy Market By Type, From 2022 - 2027 (USD Billion)
  44. Asia-Pacific Multiple Myeloma Therapeutic Proteasome Inhibitors Market By Type, From 2022 - 2027 (USD Billion)
  45. Asia-Pacific Bortezomib (Velcade) Market By Region, From 2022 - 2027 (USD Billion)
  46. Asia-Pacific Carfilzomib (Kyprolis) Market By Region, From 2022 - 2027 (USD Billion)
  47. China Multiple Myeloma Therapeutic Proteasome Inhibitors Market By Type, From 2022 - 2027 (USD Billion)
  48. India Multiple Myeloma Therapeutic Proteasome Inhibitors Market By Type, From 2022 - 2027 (USD Billion)
  49. Japan Multiple Myeloma Therapeutic Proteasome Inhibitors Market By Type, From 2022 - 2027 (USD Billion)
  50. South Korea Multiple Myeloma Therapeutic Proteasome Inhibitors Market By Type, From 2022 - 2027 (USD Billion)
  51. Australia Multiple Myeloma Therapeutic Proteasome Inhibitors Market By Type, From 2022 - 2027 (USD Billion)
  52. Asia-Pacific Multiple Myeloma Therapeutic Corticosteroids Market By Type, From 2022 - 2027 (USD Billion)
  53. Asia-Pacific Dexamethasone (Decadron) Market By Region, From 2022 - 2027 (USD Billion)
  54. Asia-Pacific Prednisone (Deltasone/Orasone) Market By Region, From 2022 - 2027 (USD Billion)
  55. China Multiple Myeloma Therapeutic Corticosteroids Market By Type, From 2022 - 2027 (USD Billion)
  56. India Multiple Myeloma Therapeutic Corticosteroids Market By Type, From 2022 - 2027 (USD Billion)
  57. Japan Multiple Myeloma Therapeutic Corticosteroids Market By Type, From 2022 - 2027 (USD Billion)
  58. South Korea Multiple Myeloma Therapeutic Corticosteroids Market By Type, From 2022 - 2027 (USD Billion)
  59. Australia Multiple Myeloma Therapeutic Corticosteroids Market By Type, From 2022 - 2027 (USD Billion)
  60. Asia-Pacific Multiple Myeloma Therapeutic Immunomodulatory Agents Market By Type, From 2022 - 2027 (USD Billion)
  61. Asia-Pacific Thalidomide (Thalomid) Market By Region, From 2022 - 2027 (USD Billion)
  62. Asia-Pacific Lenalidomide (Revlimid) Market By Region, From 2022 - 2027 (USD Billion)
  63. Asia-Pacific Arsenic trioxide (Trisenox) Market By Region, From 2022 - 2027 (USD Billion)
  64. Asia-Pacific Plerixafor (Mozobil) Market By Region, From 2022 - 2027 (USD Billion)
  65. China Multiple Myeloma Therapeutic Immunomodulatory Agents Market By Type, From 2022 - 2027 (USD Billion)
  66. India Multiple Myeloma Therapeutic Immunomodulatory Agents Market By Type, From 2022 - 2027 (USD Billion)
  67. Japan Multiple Myeloma Therapeutic Immunomodulatory Agents Market By Type, From 2022 - 2027 (USD Billion)
  68. South Korea Multiple Myeloma Therapeutic Immunomodulatory Agents Market By Type, From 2022 - 2027 (USD Billion)
  69. Australia Multiple Myeloma Therapeutic Immunomodulatory Agents Market By Type, From 2022 - 2027 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

excel
$

3335


pdf excel
$

3680


pdf excel powerbi
$

5520


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 3335

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample